<DOC>
	<DOCNO>NCT00514475</DOCNO>
	<brief_summary>The purpose study determine outcome patient mantle cell lymphoma improve add radioimmunotherapy high-dose regimen auto-transplant patient CR induction therapy .</brief_summary>
	<brief_title>Zevalin-BEAM/BEAC With Autologous Stem Cell Support Consolidation First Line Treatment Mantle Cell Lymphoma</brief_title>
	<detailed_description>Mantle cell lymphoma consider bad outcome non-Hodgkins lymphoma . Since 1997 , Nordic Lymphoma Group conduct phase II study order improve result lymphoma subtype . The first study include high-dose therapy autologous stem cell support first line treatment . The result show importance high quality response pre-transplant induction treatment , CHOP-based regimen alone achieve . Thus , second trial design improve remission include Rituximab high-dose Ara-C . Results show high rate molecular remission bone marrow achieve , 3-year FFS improve comparison first study ( 80 % vs 24 % ) . Furthermore , patient molecular relapse ( ( 11 ; 14 ) IgV-gene ) treat 4 dos Rituximab many convert back PCR negative . The present thus third phase II study aim improve high-dose regimen add Zevalin radioimmunotherapy patient CR prior transplant . Data last trial show patient CR point bad outcome ( 3 year FFS 63 % , vs 85 % CR patient ) . Monitoring molecular relapse bone marrow do , patient become PCR positive treat Rituximab order evaluate value strategy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : 1 . Age 18 65 year . 2 . Histologically confirm ( accord WHO classification ) mantle cell lymphoma stage IIIV time point diagnosis . The diagnosis confirm phenotypic expression CD5 , CD20 cyclinD1 case ( 11 ; 14 ) translocation . 3 . No previous treatment lymphoma except radiotherapy one cycle regimen except patient treat previous phase II study transfer NLGMCLIII evaluation week 15 . 4. WHO performance status 0 3 . 5 . Life expectancy 3 month . 6 . Written informed consent . 1 . Severe cardiac disease : cardiac function grade 34 ( Appendix 1 ) . 2 . Impaired liver , renal organ function cause lymphoma , interfere treatment . 3 . Pregnancy/lactation 4 . Men woman reproductive potential agreeing use acceptable method birth control treatment six moths completion treatment . 5 . Known HIV positivity 6 . Any prior malignancy nonmelanoma skin cancer stage 0 ( situ ) cervical carcinoma . 7 . Known seropositivity HCV , HbsAg active infection uncontrolled treatment . 8 . Psychiatric illness condition could interfere ability understand requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Zevalin</keyword>
	<keyword>90Y-ibritumomab tiuxetan</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>High-dose therapy</keyword>
	<keyword>First line</keyword>
</DOC>